Heart drug shows promise for non-diabetic patients with stiff heart failure
NCT ID NCT07112274
First seen Jan 03, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study looked at whether empagliflozin, a diabetes drug, can improve heart structure in people with heart failure who do not have diabetes. 50 patients with preserved ejection fraction (a type of heart failure where the heart pumps normally but is stiff) took part. Researchers measured changes in heart stress markers like NT-ProBNP and sST2 to see if the drug helps the heart remodel and work better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rehab Hussein Werida
Damanhūr, Elbehairah, 31527, Egypt
Conditions
Explore the condition pages connected to this study.